Pharmacotherapy of borderline states.
Our current state of knowledge regarding the pharmacologic management of BDs is at an early point in its evolution, exceeded only marginally by our ability to define the nosologic boundaries of these disorders. As the boundaries become better defined, especially those shared with the AD spectrum, and concurrently there is an effort to define nosologic subgroups based on differential drug treatment response, we gradually will be able to prospectively make better prescribing decisions and thereby reduce the trial-and-error aspect, with its potential for further sensitizing this population who already deal poorly with inconstancy.